Clinical Trial Update: Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating interleukin-12 after chemotherapy in patients with refractory HIV-associated non-Hodgkin lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Non-hodgkin Lymphoma

Drugs mentioned

• Interleukin-12 (interleukin-12)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma | Phase 2 | Status: COMPLETED